Merck (NYSE: MRK) and Gilead Sciences (NASDAQ: GILD) announced the discontinuation of their Phase 3 KEYNOTE-D46/EVOKE-03 study testing Gilead's Trodelvy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA